Dianthus Therapeutics, Inc.
$82.11
-1.5%Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -19.6).
Valuation inputs: P/E -19.6, earnings yield N/A, momentum -1.5%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -32.9%, ROIC -35.5%).
Profitability stack: net margin -79.7%, ROE -32.9%, ROIC -35.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +7.1%, momentum -1.5%, net margin -79.7%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Dianthus Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Dianthus Therapeutics, Inc. Fair Value Envelope
Dianthus Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Dianthus Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Dianthus Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Dianthus Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that DNTH stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 111.91, with estimates ranging from a low of 55.00 to a high of 145.00.
The consensus 1-year price target stands at 111.91, with estimates ranging from a low of 55.00 to a high of 145.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Dianthus Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $9.44M and sold $8.89M worth of DNTH shares, resulting in $545K of net buying activity.
3 Months
0
0.00
86.7K
7.05M
-7.1M
-$7.05M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
260.0K
9.44M
46.2K
1.84M
+7.6M
+$7.59M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Garcia Marino
Director, Officer: Ceo And President
$4.72M
Savitz Ryan
Officer: Cfo & Cbo
$2.44M
Randhawa Simrat
Officer: Chief Medical Officer
$2.27M
Top Sellers
Garcia Marino
Director, Officer: Ceo And President
$3.51M
Soteropoulos Paula
Director
$2.20M
Savitz Ryan
Officer: Evp, Cfo & Cbo
$1.75M
Randhawa Simrat
Officer: Evp, Head Of R&D
$1.42M
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $545K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
No Dividend Yield Data
DNTH has not reported any dividend yield values in the available annual periods.
dnth Dividend History
Learning Layer
Related Guides
Build conviction on DNTH by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.